Lung cancer genotype-based therapy and predictive biomarkers present and future

Philip T. Cagle, Timothy Craig Allen

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.-First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer.

Original languageEnglish (US)
Pages (from-to)1482-1491
Number of pages10
JournalArchives of Pathology and Laboratory Medicine
Volume136
Issue number12
DOIs
StatePublished - Dec 1 2012

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Lung cancer genotype-based therapy and predictive biomarkers present and future'. Together they form a unique fingerprint.

  • Cite this